These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 19473225)
1. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Loven D; Levavi H; Sabach G; Zart R; Andras M; Fishman A; Karmon Y; Levi T; Dabby R; Gadoth N Eur J Cancer Care (Engl); 2009 Jan; 18(1):78-83. PubMed ID: 19473225 [TBL] [Abstract][Full Text] [Related]
2. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. Argyriou AA; Chroni E; Koutras A; Iconomou G; Papapetropoulos S; Polychronopoulos P; Kalofonos HP J Pain Symptom Manage; 2006 Sep; 32(3):237-44. PubMed ID: 16939848 [TBL] [Abstract][Full Text] [Related]
3. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Argyriou AA; Chroni E; Koutras A; Ellul J; Papapetropoulos S; Katsoulas G; Iconomou G; Kalofonos HP Neurology; 2005 Jan; 64(1):26-31. PubMed ID: 15642899 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015 [TBL] [Abstract][Full Text] [Related]
5. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Vahdat L; Papadopoulos K; Lange D; Leuin S; Kaufman E; Donovan D; Frederick D; Bagiella E; Tiersten A; Nichols G; Garrett T; Savage D; Antman K; Hesdorffer CS; Balmaceda C Clin Cancer Res; 2001 May; 7(5):1192-7. PubMed ID: 11350883 [TBL] [Abstract][Full Text] [Related]
6. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. Jacobson SD; Loprinzi CL; Sloan JA; Wilke JL; Novotny PJ; Okuno SH; Jatoi A; Moynihan TJ J Support Oncol; 2003; 1(4):274-8. PubMed ID: 15334869 [TBL] [Abstract][Full Text] [Related]
7. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Mielke S; Sparreboom A; Mross K Eur J Cancer; 2006 Jan; 42(1):24-30. PubMed ID: 16293411 [TBL] [Abstract][Full Text] [Related]
8. Tracing the incidence of paclitaxel-induced peripheral neuropathy. Argyriou AA Eur J Cancer Care (Engl); 2009 Sep; 18(5):522-3. PubMed ID: 19674075 [No Abstract] [Full Text] [Related]
9. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P; J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064 [TBL] [Abstract][Full Text] [Related]
11. Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine. Choi BS; Robins HI Cancer Chemother Pharmacol; 2008 Feb; 61(2):345-6. PubMed ID: 18026678 [TBL] [Abstract][Full Text] [Related]
12. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy. Amara S Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011 [TBL] [Abstract][Full Text] [Related]
13. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582 [TBL] [Abstract][Full Text] [Related]
14. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. van der Hoop RG; Vecht CJ; van der Burg ME; Elderson A; Boogerd W; Heimans JJ; Vries EP; van Houwelingen JC; Jennekens FG; Gispen WH N Engl J Med; 1990 Jan; 322(2):89-94. PubMed ID: 2152972 [TBL] [Abstract][Full Text] [Related]